Latest pharma news

View All

Latest-pharma-happenings-for-hepion-nimbus-regeneron-bicycle-therapeutics
Hepion aces mid-stage study; Bicycle Therapeutics-Ionis collaboration; Nimbus raises $105M; Regeneron to support ISA Pharma

Hepion Pharma's NASH drug is set for Phase 2b after clearing the safety bar Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic drugs for the liver disease treatment arising from non-alcoholic steatohepatitis (NASH), declaring positive topline results from...

Find More

latest-medtech-updates-and-approval-of-devices
MedTech Market Industry: Approval of Devices, Therapy Address Market Needs | Clinical Outcomes Create New Value

LivaNova Secures FDA Approval for Clinical Study to Assess the aura6000 System for Obstructive Sleep Apnea Treatment   On June 15, 2021, LivaNova PLC received approval from the US Food and Drug Administration (FDA) to continue with its investigational device exemption (IDE) clinical study, “Treating Ob...

Find More

latest-biotech-healthcare-pharma-news-updates-aelis-farma-alcyone-progentec-gsk-kozin
Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M

Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder therapy into the clinic with a USD 30 million upfront rights agreement. Aelis, clinical-stage French biotech zeroed in on brain disorders...

Find More

latest-medtech-news-and-updates-from-abbott-bd-procyrion-tricvalve
Latest Medtech Commercial, Regulatory and Clinical Updates For – Abbott, BD, CooperVision, Procyrion, TricValve, and others

Abbott receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System for Aortic Stenosis treatment  On May 17, 2021, Abbott received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™. This marks the minimal...

Find More

recent-pharma-happenings-for-eli-lilly-mina-appia-bio-nuvalent
Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids

Lilly, MiNA ink agreement to upregulate proteins using RNA Eli Lilly will utilise the power of MiNA Therapeutics’ proprietary small activating RNA (saRNA) technology platform to develop five novel drug candidates against diseases across the company’s core areas of focus. Eli Lilly declared a drug development ...

Find More

recent-pharma-news-updates-for-artios-scholar-rock-novavax-volastra
Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M

Artios Pharma announces collaboration with Novartis to tap next-generation DDR cancer therapies Artios Pharma Limited, a leading DNA Damage Response (DDR) company exploiting synthetic lethality to create a broad pipeline of precision medicines for cancer treatment, announced a global research collaboration with ...

Find More

recent-pharma-happenings-for-asher-bio-roche-novartis-epimab
Asher Bio raises $55M; Roche halts Huntington’s phase 3 trial; Novartis’ radioligand hits goal in phase 3; EpimAb raises $120M in Series C

Asher Bio raises USD 55 Million in Series A financing Asher Biotherapeutics, a biotechnology company developing exactly targeted immunotherapies for cancer and other diseases, raised USD 55 Million in Series A financing. Third Rock Ventures led the round with participation from Boxer Capital of Tavistock Grou...

Find More

pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics
Valo Health receives $110M Series B Cognito’s therapy slows Alzheimer’s disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio

Valo Health receives USD 110 Million Series B from Koch Valo Health launched in September with USD 100 million and a couple of acquisitions under its belt to transform drug development and cut years off R&D timelines. Now, it is filling with USD 110 million from Koch Disruptive Technologies that will bolster...

Find More

latest-pharma-biotech-news-updates-for-eli-lilly-vera-therapeutics-gritstone
Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline.

Unshackling the TP53 in leukaemia with a novel combination approach. Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. However, they might be useful if they were combined.   Researchers...

Find More

recent-pharma-biotech-news-and-updates-for-zimmer-bayer-ovid-merck-janssen-roche
Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

Roche receives FDA authorization for the quantitative COVID-19 antibody test Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. The company anticipates the tes...

Find More